BI-9564

• CAT Number: I002430
• CAS Number: 1883429-22-8
• Molecular Formula: C₂₀H₂₃N₃O₃
• Molecular Weight: 353.41
• Purity: ≥95%
• Synonyms: 4-(4-((dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one
• Target: Epigenetic Reader Domain
• Solubility: DMSO: ≥ 7.2 mg/mL (Need warming)
• Storage: Store at -20°C
• IC50: Kd: 20 nM (BRD9)
• IUPAC Name: 4-[4-[(dimethylamino)methyl]-2,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one
• InChI: InChI=1S/C20H23N3O3/c1-22(2)11-13-8-19(26-5)15(9-18(13)25-4)17-12-23(3)20(24)16-10-21-7-6-14(16)17/h6-10,12H,11H2,1-5H3
• InChIKey: BJFSUDWKXGMUKA-UHFFFAOYSA-N
• SMILES: CN1C=C(C2=C(C1=O)C=NC=C2)C3=C(C=C(C(=C3)OC)CN(C)C)OC

BI-9564（Cat No.:I002430）is an experimental small molecule under investigation for its potential in treating neurological disorders, particularly those involving cognitive dysfunction and neurodegeneration. It functions as an inhibitor of a specific enzyme, targeting pathways involved in memory and learning processes in the brain. BI-9564 is being studied for its ability to enhance synaptic plasticity and potentially treat conditions like Alzheimer’s disease and other forms of dementia. Clinical trials are ongoing to evaluate its safety, efficacy, and therapeutic potential. Its success could offer a new avenue for treating cognitive impairments linked to neurodegenerative diseases.

Reference

[1]. Martin LJ, et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.

[2]. Rezaul M. Karim, et al. An Advanced Tool To Interrogate BRD9. J. Med. Chem., 2016, 59 (10), pp 4459-4461